Our results have shown that CIP2A knockout mice were resistant to DMBA induced BLBC tumour formation. Mechanistic studies indicated that it has an important role in DNA Damage Response signaling. Analysis of patient material revealed that CIP2A has a prognostic benefit particularly in basal type TNBC patients. We generated a CIP2A Biomarker signature (269 genes, p ¼ 0.01) by RNA Seq of CIP2A depleted BLBC cell lines and validated it with publicly available TCGA and METABRIC datasets. Conclusions: CIP2A is a promising novel target for BLBC and it has the potential to be used as a predictive and prognostic biomarker for BLBC. Legal entity responsible for the study: Jukka Westermarck (Principal investigator).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.